Diagnosing community-acquired pneumonia via a smartphone-based algorithm:
a prospective cohort study in primary and acute-care consultations

INTRODUCTION
Although CAP remains a leading cause of morbidity and mortality, an accurate diagnosis can be difficult and is reliant on excellent clinical skills with or without radiology. Diagnosis is more difficult in older people where symptoms and signs may be minimal, or where the presentation is modified by underlying comorbidities. Moreover, as current guidelines recommend moving towards digital consultations during the COVID-19 pandemic, diagnosing CAP is even more challenging when doctors are unable to conduct clinical examinations. There is a need to develop accurate methods to assist physicians to diagnose CAP without relying on clinical examination or radiology, with desirable features including ease of use and point-of-care results.

Globally, pneumonia is the most common cause of infectious mortality, with >2 million adults dying from lower respiratory infections in 2015.\(^1\) CAP is an essential consideration in patients presenting with respiratory symptoms. In the UK, 5%–12% of patients presenting to primary care with respiratory conditions have CAP.\(^4\) In the US, 80% of patients with CAP are managed as outpatients;\(^5\) and >8 000 000 patients with CAP are admitted to hospital annually, with an overall mortality rate of 8.8%.\(^6\)

The diagnosis of CAP relies on the presence of select clinical features (cough, fever, sputum production, and pleuritic chest pain) and abnormal vital signs (temperature, breathing, and heart rates), supported by finding new infiltrates on chest X-rays (CXRs). Despite this, clinical symptoms and signs in isolation have generally performed poorly as diagnostic criteria.\(^7\) Auscultation findings alone have poor sensitivity and demonstrate poor agreement between clinicians.\(^8–10\) Vital sign measurements are recommended to rule out CAP; a systemic review in 2019 showed validity using a combination of breathing rate, heart rate, and fever (negative likelihood ratio 0.24, 95% confidence interval [CI] = 0.17 to 0.34).\(^11\)

The utility of CXRs in diagnosing CAP is questionable. Agreement on CXR interpretation between emergency department clinicians or GPs with radiologists is poor.\(^12–14\) CXRs have been shown to lack precision, reliability, and consistency, and are not useful in determining disease aetiology.\(^15–17\) More information can be obtained from computed tomography and ultrasound examinations, but they are costly and not readily available. In primary care...
settings, access to radiology may be limited and take time, thus delaying the initiation of treatment.

Guidelines for the role of CXR in CAP diagnoses are inconsistent. The American Thoracic Society recommends routine CXRs for suspected CAP.18 The British Thoracic Society recommends CXRs for hospitalised patients but not for community treatment, unless there are additional concerns such as inadequate response to treatment.19 The European Respiratory Society recommends separating ‘definite’ from ‘suspected’ CAP based on the presence or absence of an abnormal CXR; then treating both groups with empirical antibiotics.20 Most CAPs in the UK are thus diagnosed using clinical features alone.

In 2015, the authors commenced a digital diagnostic program to develop algorithms that combine a mathematical analysis of cough-associated audio segments with patient-reported symptoms to identify respiratory diseases in children and adults.21–23 The forced expiratory air column produced during a cough supports a higher bandwidth than that across the chest wall, which is relied on in traditional auscultation. Sounds generated inside the lungs propagate through this air column and the pathophysiological changes caused by different respiratory conditions modulate the sound quality. The identification of unique sound signatures characteristic of different conditions led to the development of algorithms for the diagnosis of each respiratory condition. The algorithms do not rely on the input of vital signs, clinical examination, or radiographs.

A pilot study using this method demonstrated a sensitivity of 94% and specificity of 88% for differentiating pneumonia from no disease.24 Subsequently, the authors published the accuracy of an algorithm to differentiate paediatric patients with croup, asthma, pneumonia, bronchiolitis, and upper/lower respiratory disease.25 The PPA and NPA for pneumonia in children aged 2–12 years were 85% and 80%, and for >28 days to 2 years, 100% and 97%. The aim of the current study was to develop and test the performance of an algorithm to diagnose CAP in an adolescent and adult population presenting to primary and acute-care settings with respiratory symptoms.

METHOD
Study design
A prospective cohort study comparing the diagnostic accuracy of an automated algorithm to clinical diagnosis of CAP in participants aged >12 years attending acute-care units in an Australian hospital.

Study population and setting
Between January 2016 and March 2019, the study recruited two cohorts as convenience samples from a large, general hospital in Western Australia. Data from the first cohort were used to develop and optimise the software algorithm. The second, independent cohort was used to test the optimised algorithm.

Participants came from multiple hospital departments, including the primary care unit, emergency department, and inpatient wards. Participants were approached if they presented with signs or symptoms of acute respiratory disease. All participants who met the inclusion criteria were eligible, except for those with documented chronic obstructive pulmonary disease (COPD) or restrictive lung disease (diagnostic algorithms have already been developed for these by the authors). Inclusion/exclusion criteria are presented in Table 1.

Study protocol
The study did not interfere with clinical care. There were no adverse events reported.

Cough recording
Different operators collected cough recordings at the time of enrolment using iPhone 6 smartphones held 25 cm to 50 cm from the mouth out of direct air flow. Recordings occurred in typical environments with background noises (talking, medical devices, footsteps, and doors).

Participants provided five voluntary coughs. The procedure took <1 minute to perform. Recording coughs from other people or television sounds were avoided.
Clinical data
Data collected included the treating physician’s final diagnosis; the patient’s demographics, medical history, presenting symptoms, vital signs, examination findings, response to treatments; and results of investigations performed.

Clinical examination
A full medical assessment was performed on all participants at time of enrolment.

Table 1. Study inclusion and exclusion criteria

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt;12 years and at least one of the following:</td>
<td>Lack of consent</td>
</tr>
<tr>
<td>Rhinorrhea</td>
<td>Ventilatory support</td>
</tr>
<tr>
<td>Sore throat</td>
<td>Terminal disease</td>
</tr>
<tr>
<td>Sneezing (during this illness)</td>
<td>Medical contraindication to voluntary coughing:</td>
</tr>
<tr>
<td>Cough [acute, chronic, or productive]</td>
<td>Severe respiratory distress</td>
</tr>
<tr>
<td>Wheeze</td>
<td>History of pneumothorax</td>
</tr>
<tr>
<td>Fever</td>
<td>Eye chest or abdominal surgery in the past 3 months</td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>Uncontrolled acute heart failure (chronic heart failure was not an exclusion)</td>
</tr>
<tr>
<td>New-onset hoarse voice (during this illness)</td>
<td>History of neuromuscular disease</td>
</tr>
<tr>
<td></td>
<td>History of lobectomy/pneumonectomy</td>
</tr>
<tr>
<td></td>
<td>Diagnosed chronic obstructive pulmonary disease or restrictive lung disease</td>
</tr>
</tbody>
</table>

Table 2. Clinical diagnosis definition

<table>
<thead>
<tr>
<th>Community-acquired pneumonia (CAP)</th>
<th>Must have:</th>
</tr>
</thead>
<tbody>
<tr>
<td>New (≤7 days) respiratory symptoms [shortness of breath, cough, chest pain]</td>
<td></td>
</tr>
<tr>
<td>Acute fever within the last week</td>
<td></td>
</tr>
<tr>
<td>Treating team diagnosis of CAP and treated with antibiotics includes:</td>
<td></td>
</tr>
<tr>
<td>Radiology confirmed CAP: radiologist-reported new consolidation or significant infiltrate on the CXR or consolidation on CT.</td>
<td></td>
</tr>
<tr>
<td>Not radiologically confirmed CAP: either no CXR performed or no consolidation/infiltrate on CXR.</td>
<td></td>
</tr>
</tbody>
</table>

CT = computed tomography; CXR = chest X-ray.

Clinical diagnosis of CAP (reference test)
Table 2 shows the definition of CAP [as per European Respiratory Society20]. The medical record for each patient was reviewed by an independent physician who took into consideration all available laboratory/radiology results and clinical examination findings to confirm a final clinical diagnosis. Pneumonia severity was assessed using the CRB-65.25 After a clinical diagnosis was assigned the database was locked to further input.

Development of the algorithm (index test)
Between January 2016 and November 2017, the study recruited participants to train and refine the algorithm. The mathematical techniques used to derive the algorithms have been described elsewhere.21,23,24 Briefly, selected cough audio-segments and patient-reported symptoms were extracted from the training cohort and combined into several continuous classifier models to determine the probability of CAP. A logistic-regression model was trained to diagnose CAP. The optimal model and corresponding probability decision thresholds were selected using a receiver operating characteristic (ROC) curve with due consideration given to achieving a balance of PPA and NPA.24 The algorithm represents the weighted combination of clinical and cough derived features used.

Diagnostic accuracy study of the optimised diagnostic algorithm
Participants from the same locations were recruited as the training set, using the same inclusion/exclusion criteria, for the prospective diagnostic accuracy trial. Automatic segmentation was used to extract five coughs for analysis. For each subject, the algorithm reached a decision using audio-data, plus input from four patient-reported symptoms: presence of fever in the past week, presence of either acute (≤7 days) cough or productive cough, and age. An independent operator ran the algorithm on the testing set to ensure blinding.

Statistical analysis
As a clinical diagnosis of CAP is not a gold-standard reference, PPA and NPA were used as primary measures of diagnostic agreement, rather than sensitivity or specificity. PPA reports clinical diagnosis-positive cases who are also index test positive, whereas NPA reports clinical diagnosis-negative cases who are also index test negative. Results that were unsure (reference test) or missing (index test) were excluded from analysis.
Power calculations were derived based on expected PPA and NPA >85% from the training program. A minimum of 48 cases were required. Ninety-five per cent CIs were calculated using the method of Clopper–Pearson. The probability of a positive clinical diagnosis was calculated by the final classifier model and was used as the decision thresholds in derived ROC curves with area under curve (AUC) calculations.

Results are shown for the entire cohort and the following age groups: 12–<22 years; ≥22 years; 22–<65 years, and ≥65 years. These age groupings are consistent with both Food and Drug Administration regulatory and CRB-65 guidelines.25,26

The cough recordings are not available but will be uploaded as an educational tool in the future.

Table 3. Characteristics of participants included and excluded from the analysis. Data includes all subjects in each age group (CAP positive and negative)

<table>
<thead>
<tr>
<th>Age, years</th>
<th>Total cohort, all ages (n = 322)</th>
<th>Age 12–&lt;22 years (n = 44)</th>
<th>Age ≥22 years (n = 278)</th>
<th>Age 22–&lt;65 years (n = 192)</th>
<th>Age ≥65 years (n = 86)</th>
<th>Non-analysed (n = 9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>Mean ±SD</td>
<td>48.5 ±22.0</td>
<td>16.3 ±3.1</td>
<td>53.6 ±19.2</td>
<td>43.1 ±12.4</td>
<td>77.0 ±7.5</td>
</tr>
<tr>
<td></td>
<td>Median (IQR)</td>
<td>48.5 (30.0–66.0)</td>
<td>16.0 (13.0–19.0)</td>
<td>53.0 (37.0–69.0)</td>
<td>43.0 (31.0–54.0)</td>
<td>75.0 (71.0–84.0)</td>
</tr>
<tr>
<td>Sex, n(%)</td>
<td>Male</td>
<td>124 (38.5)</td>
<td>20 (45.5)</td>
<td>104 (37.4)</td>
<td>68 (35.4)</td>
<td>36 (41.9)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>198 (61.5)</td>
<td>24 (54.5)</td>
<td>174 (62.6)</td>
<td>124 (64.6)</td>
<td>50 (58.1)</td>
</tr>
</tbody>
</table>

*IQRs are shown as Q1–Q3. Q1 = the median of the lower half of the data, and Q3 = the median of the upper half of the data. CAP = community-acquired pneumonia. IQR = interquartile range.
Participants without CAP (n = 163) had a primary diagnosis of upper respiratory tract infection (n = 50), non-pneumonic lower respiratory infection including acute bronchitis not reaching CAP definition (n = 32), acute asthma (n = 23), chronic obstructive airway disease (n = 22), allergy (n = 21), and non-respiratory disease (n = 15) (data not shown).

The PPA and NPA of the algorithm with clinical diagnosis and AUC are shown in Table 5. The ROC curves are shown in Supplementary Figures S1a, S1b, and S1c.

For the total cohort, PPA was 86.2% (95% CI = 79.8 to 91.1) and NPA was 86.5% (95% CI = 80.3 to 91.3). Accuracy was preserved across age groups: ≥65 years (PPA = 85.7%, NPA = 87.5%, AUC = 0.95) and 22–<65 years (PPA = 85.7%, NPA = 87.0%, AUC = 0.94).

Participants with CAP had a CRB-65 severity score of 0 in 40.8% (n = 65/159) and between 1–2 in 59.2% (n = 94/165). CAP severity did not affect accuracy: 85.1% (n = 80/94) of participants with CRB-65 scores 1–2, and 87.7% (n = 57/65) with a score of 0 were correctly diagnosed (data not shown).

In participants aged 12–22 years (n = 44), five had CAP. All five were correctly diagnosed, while 6 of 39 participants without CAP incorrectly tested positive (data not shown).

Despite the increasing prevalence of comorbidities (heart failure and smoking history) in participants aged ≥65 years with CAP (Table 4) the accuracy was not reduced compared to the younger, healthier subgroup of 22–<65 years.

A sensitivity analysis including only participants with an acute cough improved the PPA of the total cohort from 86.2% to 92.5% (95% CI = 86.6% to 96.3%); however, significantly decreased the NPA from 86.5% to 42.1% (95% CI = 26.3% to 59.2%) and the AUC decreased from 0.95 to 0.62.

### Table 4. Symptoms and past medical history of participants. Data includes all participants in each age group (CAP positive and negative)

<table>
<thead>
<tr>
<th>Symptoms during this illness</th>
<th>Total cohort, all ages (n = 322), n(%)</th>
<th>Age 12–&lt;22 years (n = 44), n(%)</th>
<th>Age ≥22 years (n = 278), n(%)</th>
<th>Age 22–&lt;65 years (n = 192), n(%)</th>
<th>Age ≥65 years (n = 86), n(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute cough (&lt;7 days)</td>
<td>171 (53.1)</td>
<td>12 (27.3)</td>
<td>159 (57.2)</td>
<td>97 (50.5)</td>
<td>62 (72.1)</td>
</tr>
<tr>
<td>Chronic cough (&lt;28 days)</td>
<td>18 (5.6)</td>
<td>2 (4.5)</td>
<td>16 (5.8)</td>
<td>9 (4.7)</td>
<td>7 (8.1)</td>
</tr>
<tr>
<td>Productive cough</td>
<td>114 (35.4)</td>
<td>9 (20.5)</td>
<td>105 (37.8)</td>
<td>61 (31.8)</td>
<td>44 (51.2)</td>
</tr>
<tr>
<td>Fever</td>
<td>145 (45.0)</td>
<td>13 (29.5)</td>
<td>132 (47.5)</td>
<td>83 (43.2)</td>
<td>49 (57.0)</td>
</tr>
<tr>
<td>Runny nose</td>
<td>127 (39.4)</td>
<td>9 (20.5)</td>
<td>118 (42.4)</td>
<td>78 (40.6)</td>
<td>40 (46.5)</td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>133 (41.3)</td>
<td>7 (15.9)</td>
<td>126 (45.3)</td>
<td>74 (38.5)</td>
<td>52 (60.5)</td>
</tr>
<tr>
<td>Wheeze</td>
<td>37 (11.5)</td>
<td>3 (6.8)</td>
<td>34 (12.2)</td>
<td>17 (8.9)</td>
<td>17 (19.8)</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>65 (20.2)</td>
<td>9 (20.5)</td>
<td>56 (20.1)</td>
<td>40 (20.8)</td>
<td>16 (18.6)</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>30 (9.3)</td>
<td>4 (9.1)</td>
<td>26 (9.4)</td>
<td>18 (9.4)</td>
<td>8 (9.3)</td>
</tr>
<tr>
<td>Lethargy</td>
<td>158 (49.1)</td>
<td>12 (27.3)</td>
<td>146 (52.5)</td>
<td>89 (46.4)</td>
<td>57 (64.3)</td>
</tr>
<tr>
<td>Loss of appetite</td>
<td>82 (25.5)</td>
<td>8 (18.2)</td>
<td>74 (26.6)</td>
<td>37 (19.3)</td>
<td>37 (43.0)</td>
</tr>
<tr>
<td>Hoarse voice</td>
<td>55 (17.1)</td>
<td>5 (11.4)</td>
<td>50 (18.0)</td>
<td>34 (17.7)</td>
<td>16 (18.6)</td>
</tr>
<tr>
<td>Past medical history</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic respiratory disease</td>
<td>59 (18.3)</td>
<td>11 (25.0)</td>
<td>48 (17.3)</td>
<td>30 (15.6)</td>
<td>18 (20.9)</td>
</tr>
<tr>
<td>Atopy</td>
<td>51 (15.8)</td>
<td>4 (9.1)</td>
<td>47 (16.9)</td>
<td>40 (20.8)</td>
<td>7 (8.1)</td>
</tr>
<tr>
<td>Heart failure (controlled)</td>
<td>30 (9.3)</td>
<td>0 (0.0)</td>
<td>30 (11.8)</td>
<td>2 (1.0)</td>
<td>28 (32.6)</td>
</tr>
<tr>
<td>Smoker (ever)</td>
<td>131 (40.7)</td>
<td>9 (20.5)</td>
<td>122 (43.9)</td>
<td>84 (43.8)</td>
<td>38 (44.2)</td>
</tr>
</tbody>
</table>

For the total cohort, PPA was 86.2% (95% CI = 79.8 to 91.1) and NPA was 86.5% (95% CI = 80.3 to 91.3). Accuracy was preserved across age groups: ≥65 years (PPA = 85.7%, NPA = 87.5%, AUC = 0.95) and 22–<65 years (PPA = 85.7%, NPA = 87.0%, AUC = 0.94).

Participants with CAP had a CRB-65 severity score of 0 in 40.8% (n = 65/159) and between 1–2 in 59.2% (n = 94/165). CAP severity did not affect accuracy: 85.1% (n = 80/94) of participants with CRB-65 scores 1–2, and 87.7% (n = 57/65) with a score of 0 were correctly diagnosed (data not shown).

In participants aged 12–22 years (n = 44), five had CAP. All five were correctly diagnosed, while 6 of 39 participants without CAP incorrectly tested positive (data not shown).

Despite the increasing prevalence of comorbidities (heart failure and smoking history) in participants aged ≥65 years with CAP (Table 4) the accuracy was not reduced compared to the younger, healthier subgroup of 22–<65 years.

A sensitivity analysis including only participants with an acute cough improved the PPA of the total cohort from 86.2% to 92.5% (95% CI = 86.6% to 96.3%); however, significantly decreased the NPA from 86.5% to 42.1% (95% CI = 26.3% to 59.2%) and the AUC decreased from 0.95 to 0.62.

### Table 5. PPA and NPA and calculated AUC of the software algorithm compared with a clinical diagnosis of CAP

<table>
<thead>
<tr>
<th></th>
<th>PPA, % (95% CI) (n = CAP positive)</th>
<th>NPA, % (95% CI) (n = CAP negative)</th>
<th>AUC (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cohort (N=322)</td>
<td>86.2 (79.8 to 91.1) (n = 159)</td>
<td>86.5 (80.3 to 91.3) (n = 163)</td>
<td>0.95 (0.93 to 0.97)</td>
</tr>
<tr>
<td>22–&lt;65 years (N=192)</td>
<td>85.7 (76.4 to 92.4) (n = 84)</td>
<td>87.0 (79.2 to 92.7) (n = 108)</td>
<td>0.94 (0.91 to 0.97)</td>
</tr>
<tr>
<td>≥65 years (N=86)</td>
<td>85.7 (75.3 to 92.9) (n = 70)</td>
<td>87.5 (61.7 to 98.4) (n = 16)</td>
<td>0.95 (0.91 to 0.97)</td>
</tr>
</tbody>
</table>

AUC = area under curve. CAP = community-acquired pneumonia. NPA = negative percentage agreement. PPA = positive percentage agreement.
DISCUSSION

Summary
The authors have developed and tested a mathematical algorithm for diagnosing CAP using cough sound analysis and patient-reported symptoms. The algorithm showed a high degree of agreement with clinician diagnosis (utilising all clinical and imaging modalities) with accuracy maintained across age groups and severity indices. The tool does not rely on the input of vital signs, clinical examination, or radiological findings, and delivers an immediate, point-of-care result.

Strengths and limitations
The study design ensured the independence of the training/testing sets and the clinical/algorithm diagnostic teams. This study applied stringent criteria, utilising all available medical and imaging data, to determine a clinical diagnosis that was as accurate as possible. The reference diagnosis of CAP was confirmed after patient discharge, whereas the algorithm provided diagnosis at the time of presentation. The study implemented this rigorous process as studies have shown up to 30% discordance between initial and final diagnoses of pneumonia.27–29

This study builds on the authors' work diagnosing pneumonia in children aged 1 month to 12 years (PPA 85%, NPA 80%).21 The numbers in this study exceeded that required by power calculations, except in the 12–<22 years age group. Although there was good agreement between the algorithm and clinical diagnoses, and the authors have no reason to consider that diagnostic accuracy would not be maintained across this age group, it would be helpful to confirm this in a larger study.

This study population was from a first-world metropolitan hospital. It will be important to replicate the study in general practice, digital, and other settings to assess diagnostic accuracy and user experience. As the algorithm is site and operator-independent, the authors believe that the results of the study are generalisable to community use. It was encouraging to note the high rate of usable cough datasets.

The inclusion criteria did not distinguish between microbiological aetiologies of CAP. Determining the organism, or organisms, responsible is difficult and unreliable in most settings, and, consequently, CAP is routinely treated with antibiotics. Using polymerase chain reaction testing, along with standard microbiological techniques, has shown that a majority of cases have >1 organism and that, in winter at least, mixed viral-bacterial infections are more common than pure bacterial or viral.30 As the study was performed before the SARS-CoV-2 pandemic participants with this aetiology were not included.

A diagnostic concern in elderly patients presenting with respiratory symptoms is differentiating acute heart failure from CAP. The authors were pleased to see that the accuracy was preserved in the ≥65 years age group, which had a higher prevalence of chronic heart failure.

Judging the severity of CAP is crucial when managing CAP and can be determined using the CRB-65, as recommended in UK guidelines.19 CRB-65 uses an assessment of mental state and vital signs (including blood pressure) to stratify the severity of pneumonia and 30-day mortality in hospitals, and suggest where management should occur.31 Using the CRB-65, 40.8% of this study’s CAP-positive cohort scored 0 (1.2% risk of 30-day mortality, suitable for community treatment) and 59.2% scored 1 or 2 (8.2% risk of 30-day mortality, hospital referral recommended).31 The study found no differences in the diagnostic accuracy of the algorithm between these groups. As the study excluded patients with severe respiratory distress, the severity of CAP in this study represents the population seen in general practice despite being hospital sourced. The authors anticipate that it would be more difficult to clinically diagnose pneumonias of lower severity. The ability of this algorithm to identify lower severity CAP is encouraging for its potential use in primary care.

Comparison with existing literature
Many authors have reported on the difficulties of diagnosing CAP, and this is reflected in inconsistent management guidelines. Most have focussed on the relative merits of clinical features, examination findings, and CXR, with very few reporting on digital diagnostic tools.32 The authors’ prior work has shown that it is possible to identify cough-sound streams that are characteristic of different respiratory disorders, including lower versus upper airway disease, COPD, COPD exacerbations, and asthma exacerbations in adults, and focal pneumonia, croup, and bronchiolitis in children.21

In the absence of radiology, GPs are reliant on empirical diagnosis of CAP using auscultation or clinical signs resulting in a significant proportion (71%) of radiologically-confirmed CAP cases.

Funding
ResApp Health [RAP] provided funding to support the Breathe Easy Program at Joondalup Health Campus (JHC) and University of Queensland (UQ). JHC provided office space, IT services, and consumables in kind.

Ethical approval
Ethical approval was obtained from the Human Research Ethics Committees of Princess Margaret Hospital (reference number: 2015030EP), JHC [reference number: 1501], Curtin University [reference number: HRE2018–0016] and The UQ [reference number: 2015000395/2016.01.179]. All participants, parents, or guardians signed a consent to participate form. This work has been reported in accordance with the Standards for Reporting Diagnostic Accuracy studies (STARD). The trial is registered with the Australian and New Zealand Clinical Trials Registry [The Breathe Easy Study: ACTRN 12618001521213].
being missed in primary care. Clinical signs and symptoms have previously been shown to perform poorly in the diagnosis of CAP. This study’s algorithm provides high diagnostic accuracy in the absence of radiology and without the need to examine the patient.

Implications for practice
The NHS has advised it expects all patients to have the right to be offered digital-first primary care by 2023–2024 with estimates that up to one-third of face-to-face GP visits could be replaced by telehealth each year. In April 2020, during the COVID-19 pandemic, 71% of all GP visits in the UK were conducted remotely, compared to 25% pre-pandemic. Over 30% of telehealth consultations are for respiratory disease.

During the pandemic, the National Institute for Health and Care Excellence recommended that clinicians should not consult face-to-face or perform auscultation for CAP diagnosis unless essential. Instead, they suggest visual observation for breathlessness and cyanosis, and using clinical ‘gestalt’ or vital signs (including temperature, and heart and respiratory rates) to rule out CAP. This would be challenging over a telephone or video call.

The authors have demonstrated that their algorithm can accurately identify CAP of varying severity, without clinical or radiological inputs. Its rapid output and smartphone platform make it suited for both traditional and digital consultations where it can assist in CAP diagnosis using only cough sounds and four patient-reported symptoms.

The algorithm is incorporated into a platform to identify multiple respiratory disorders and may enhance the capabilities of community telehealth services, with implications for reducing the duration of illness, minimising complications, and promoting good antibiotic stewardship.

The platform has regulatory approval for use in Europe and Australia. It is available on Australian telehealth platforms.

With current recommendations to use digital consultations during the pandemic, as well as the uptake of remote consultations globally, this tool presents an opportunity to use digital diagnostics to enhance telemedicine consultations.

Provenance
Freely submitted; externally peer reviewed.

Competing interests
Paul Porter, Scott Claxton, and Udantha Abeyratne are scientific advisors of RAP. Paul Porter and Udantha Abeyratne are shareholders in RAP. Udantha Abeyratne was RAP’s chief scientist. RAP is an Australian publicly listed company commercialising the technology under license from the University of Queensland, where Udantha Abeyratne is employed. Udantha Abeyratne is a named inventor of the UQ technology. Vesa Peltonen and Javan Wood are employees of RAP. Natasha Bear received consulting fees for statistical analysis. Joanna Brisbane, Claire Smith, and Phillip Della have declared no competing interests.

Acknowledgements
The authors wish to thank the many patients and their families who have given their time and enthusiasm for this work.

Open access
This article is Open Access: CC BY 4.0 licence (http://creativecommons.org/licenses/by/4.0/).

Discuss this article
Contribute and read comments about this article: bjgp.org/letters
REFERENCES